Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL-018 vs Xolair in chronic idiopathic urticaria
NCT05774639Phase 3Completed
- Sponsor
- Kashiv BioSciences
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of adl018 in chronic idiopathic urticaria (CIU), sponsored by Kashiv BioSciences. Started Aug 2023; status: completed.
02
Drugs
adl018
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT05774639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774639.